Skip to main content

Participate in Research

Would you like to be a part of ground breaking medical research? Researchers in our faculty frequently undertake clinical trials to test new medical treatments and interventions. Your participation is crucial to improving the health of our population. Explore our currently enrolling trials below.

What is a clinical trial, and why do we need them?

Clinical trials are research studies that involve human volunteers who are assigned to one or more health-related interventions to evaluate the effects on health outcomes. Clinical trials are essential for the development of new medical treatments and interventions. They are used to determine if a new intervention works, if it is safe, and whether or not it is an improvement on currently available treatments.

The following trials are currently seeking participants:

Adolescents resisting the drinking culture

Understanding abstinence or low risk alcohol consumption in adolescence

Significant numbers of Australian adolescents consume alcohol, with almost two thirds of them doing so at risky levels. As a consequence, the consumption of alcohol by Australian adolescents remains a national concern. The aim of this study is to establish new insights in the social phenomenon of adolescent drinking in Australia by applying an alternative lens and exploring what influences adolescents’ decisions to abstain, refrain or consume alcohol at low risk levels.  This study is part of a PhD being conducted in the Adelaide Nursing School, with Associate Professor Lynette Cusack as the Principal Investigator and Sue Sharrad as the PhD candidate.

As there is limited understanding of this phenomenon, this research is important for future health promotion and education strategy directions. 

Eligibility requirements

To be eligible for the study, participants must be male or female adolescents, aged between 14 – 19 years of age, and either an abstainer, or low risk consumer of alcohol or can describe experiences where they have refrained from alcohol consumption.  Study participants must be able to commit to an interview that may last one to two hours.

Contact details for registration of interest

Student researcher and PhD candidate Sue Sharrad at or phone 0414 383 349.

HREC Approval No: H-2016-217

Bending and Lifting Study

The Adelaide Centre for Spinal Research (SA Pathology), UniSA and the University of Adelaide, seeks 30-70 year-old male and female volunteers to participate in a study investigating methods of bending and lifting light weights (less than 10kg).

Eligibility requirements

Individuals in two categories are invited to participate in this study:

  1. Individuals in good health without persistent back pain
  2. Individuals with persistent low back pain for at least three months

Participants will receive a $50 gift voucher. This study has been approved by the Research Ethics Committee of the Royal Adelaide Hospital. 

Contact details for registrations of interest

If you would like to find out more about this study, please email: or call: 0478 753 014.

Cognitive and Functional Assessment of Psychosis Staging Study (CoFAPSS)

Cognitive and Functional Assessment of Psychosis Staging Study (CoFAPSS) is a South Australian multicentre study of the impact of psychotic illness on symptoms, cognitive (thinking) and general function. Our aim is to identify key predictors of good or poor function that can be used to help select the best treatments as early as possible in a person’s illness to produce the best outcome.

Eligibility requirements

To be eligible for the study, participants must be 16 to 65 years of age and have a past or current history of symptoms of psychotic illness. We are also interested in assessing control subjects with no history of psychosis and / or family members of patients with psychosis.

Study participants would need to attend one of the Discipline of Psychiatry sites at the Queen Elizabeth Hospital or the new Adelaide Health and Medical Sciences building on North Terrace, Adelaide. 

Contact details for registrations of interest

Study co-ordinator Dr Scott Clark at

ENDIA - Australia's largest study into the causes of Type 1 Diabetes in childhood

Type 1 Diabetes in children is twice as common as it was 20 years ago. To understand why, the ENDIA (Environmental Determinants of Islet Autoimmunity) Study is the world’s first to follow children from the pregnancy to determine what factors influence the development of type 1 diabetes (T1D).

This national study aims to follow 1400 babies who have a first degree relative with T1D. The study assesses environmental exposures and how these protect from or trigger the onset of T1D. ENDIA is an observational study; there are no interventions and participation is low risk.

Eligibility requirements

Family members who meet the following criteria may be eligible for ENDIA:

  • Pregnant women with T1D
  • Men with T1D whose partner is pregnant
  • Pregnant women with an older child who has T1D
  • Babies less than 6 months of age who have a first degree relative with T1D.

Contact details for registrations of interest

To express your interest in the study contact ENDIA by email or via the website at, or call our nurse coordinators directly: Adelaide - (08) 8161 7349; Brisbane – (07) 3163 1759; Geelong – 0478 336 610; Melbourne – (03) 9342 8641; Newcastle – 0408 162 559; Perth – (08) 9340 7974; Sydney – (02) 9832 9243; ALL OTHER AREAS – (08) 8161 8655.

Recruitment continues into 2018. ENDIA also has a Regional Participation Program for those living too far from ENDIA sites to be able to participate from their home.

ENDIA is also on Facebook for regular news and updates. Please like or share our posts to spread the word!

This study has ethical approval and current funding from JDRF Australia and the Helmsley Charitable Trust.

Exenatide (once weekly) trial

Exenatide BD (also known as Byetta) is a drug that is used to manage blood sugar (glucose) levels in people with type 2 diabetes. It is widely used today and is injected twice daily. One of the ways in which Byetta works is by slowing the rate of stomach emptying and thereby reducing blood sugar levels. A once weekly preparation of exenatide (Bydureon) has now been approved for use in Australia. We plan to evaluate the effect of this medication on the rate of stomach emptying in healthy subjects. This study will provide important information relating to the mechanism of action of this drug in the management of people with type 2 diabetes.

Eligibility requirements

To be eligible for the study, we are looking for healthy (non-diabetic) male and female participants between 55 and 70 years of age (females must be postmenopausal), and in general good health. Study participants are required to attend the Discipline of Medicine at the Royal Adelaide Hospital once a week for the 9 week duration of the exenatide QW (Bydureon) treatments. At the beginning and end of the 9 week period, participants will have their rate of stomach emptying measured using a non-invasive technique.

Contact details for registrations of interest

Study co-ordinators: Mrs Rachael Tippett & Ms Seva Hatzinikolas. Phone 0451 735 247 or email

Gastrointestinal mechanisms underlying glucose lowering by metformin in type 2 diabetes

Metformin is the most widely used drug for blood sugar control in type 2 diabetes. Recent evidence suggests that its anti-diabetic action is predominantly mediated through the gut. In this study, we want to compare the effects of metformin when administered into upper and lower small intestine in people with type 2 diabetes. Involvement in this trial requires attendance at a 30-45-minute screening visit followed by 3 study days in the department (Royal Adelaide Hospital, Eleanor Harrald building level 6, Discipline of Medicine), divided over at least 3 weeks, where metformin is administered and its effects analysed. No overnight stays or involvement is required between study days.

Eligibility requirements

To be eligible for the study, participants must be between 18 and 75 years of age and have diet-controlled type 2 diabetes. As part of the aforementioned screening visit, volunteers will be examined further for eligibility via a questionnaire, height and weight measurement and analysis of sampled blood.

Contact details for registrations of interest

Should you wish to be involved in the study or have any questions or concerns, please contact any of:

  • Mr Malcolm Borg, Honours Student, University of Adelaide, Discipline of Medicine, Royal Adelaide Hospital; phone: 8222 5039; email:
  • Dr Tongzhi Wu, MD, PhD, Royal Adelaide Hospital Research Committee Early Career Fellow, University of Adelaide Discipline of Medicine, Level 6 Eleanor Harrald building, Royal Adelaide Hospital; phone: 82225038; email:
  • Ms Michelle Bound, B Med Rad (Nuc Med), Research Officer, University of Adelaide Discipline of Medicine, Royal Adelaide Hospital; phone: 8222 5039; email:

Imagination and ESP

This study aims to find out about a particular form of extra-sensory perception (ESP) known as precognition (correctly predicting a future target photograph from a set of five before the target is selected by a random number generator).

You will be required to complete a few questionnaires. This will be done in person at the School of Psychology. This should all take no longer than 30 to 40 minutes. Participants may also find benefit in contributing to potentially valuable psychological research, as well as gaining experience and knowledge in methods of psychological testing.

Eligibility requirements

In order to be eligible for participation in this study, you must be 18 years or over, and be able to speak/read English fluently.

Contact details for registrations of interest

Dr Lance Storm
Text “ESP” to 0437 032 556
Email with the subject “ESP”

Dr Storm will respond as soon as possible with office location and available testing times.

Ketamine Adult Depression Study

The Ketamine for Adult Depression Study (KADS) is a multi-centre trial across Australia and New Zealand, investigating the use of ketamine for treatment resistant depression. The KADS Adelaide site is run by the Discipline of Psychiatry, with Professor Bernhard Baune as the Principal Investigator.

Ketamine is a medication used for anaesthesia, sedation and pain relief. However in this study, ketamine is given in much lower doses than those used for anaesthesia. Low dose ketamine has been found to reduce symptoms of depression rapidly and effectively, but the use of ketamine in treating depression is still under investigation.

Eligibility requirements

To be eligible for the study, participants must be 18 years of age or over, with current Major Depressive Disorder that has not improved with other treatments. Study participants would also need to be able to attend the Discipline of Psychiatry twice per week for the course of ketamine treatments.

Contact details for registrations of interest

Study co-ordinator Dr Natalie Mills at

MAGENTA: Magnesium sulphate at 30 to 34 weeks' gestational Age: Neuroprotection Trial

Babies born very preterm have a greater risk of significant morbidities including neurologic impairments such as cerebral palsy. The risk of morbidity increases with decreasing gestational age at birth. The Cochrane review evaluating the effect of magnesium sulphate on neuroprotection of the fetus shows that magnesium sulphate given to women at risk of imminent preterm birth reduces the risk of cerebral palsy. It remains unclear at which gestational age treatment will be beneficial.

The National Clinical Practice Guidelines on Antenatal Magnesium Sulphate prior to preterm birth of the fetus, infant and child recommends further randomised trials at 30 weeks' gestation or more. This had led to the MAGENTA Study.

Chief Investigators: Prof Caroline Crowther, Ms Philippa Middleton, A/Prof Dominic Wilkinson, A/Prof Ross Haslam

Clinical Trial Coordinator: Ms Pat Ashwood, Ms Daniela Gagliardi, Ms Michaela Jarrett


Phone:+61 8 8161 7767


Mind and Brain Research at SAHMRI

If you have encountered depression, anxiety, stress or chronic fatigue in your daily life, consider contributing to research at SAHMRI

Pancreatic Enzyme Replacement Therapy (PERT) trial

The pancreatic enzyme replacement therapy (PERT) trial is a short-term study investigating the impact of pancreatic enzyme replacement therapy in type 2 diabetic patients with pancreatic exocrine insufficiency. The trial is conducted within the Discipline of Medicine at the University of Adelaide, with Dr. Liza Phillips as the Principal Investigator.

Recent literature has shown that the prevalence of pancreatic exocrine insufficiency exists in up to 1 in 5 patients with type 2 diabetes. Pancreatic exocrine insufficiency may lead to an inappropriate rise in blood glucose levels after a meal and it is proposed that pancreatic enzyme replacement medication may offset this effect. This trial aims to prove and characterise this phenomenon.

Eligibility requirements

To be eligible for the study, participants must have type 2 diabetes and be between 40-80 years of age. Participants cannot be on exenatide (Byetta) for this trial. Participants must be willing to provide a faecal sample and attend the Discipline of Medicine for a short screening visit and then, if eligible, for two study days that last 7 hours each day. Those who complete the two study days will be reimbursed $18/hour for their time.

Contact details for registrations of interest

Study co-ordinator Dr Liza Phillips at or (08) 8222 2915.